CJC-1295 FAQ: DAC vs no-DAC, dosing, and ipamorelin

Last updated 2026-07-30

What is CJC-1295 and how does it work?

CJC-1295 is a synthetic peptide built to mimic growth-hormone-releasing hormone (GHRH), the hormone your hypothalamus releases to tell the pituitary gland to make and release growth hormone. The molecule is engineered from the first 29 amino acids of native GHRH with substitutions that make it more stable in the bloodstream than the natural hormone, which normally breaks down in minutes ^[1]. The defining feature of the original CJC-1295 molecule is a chemical tag called DAC (Drug Affinity Complex), which lets the peptide bind to albumin, a protein that circulates in blood. That binding is what stretches its activity out over days instead of minutes. In the human trial that put this peptide on the map, a single injection of CJC-1295 with DAC produced a sustained rise in growth hormone and IGF-1 that lasted roughly 6 to 9 days, with mean GH increases and IGF-1 levels that stayed above baseline for about a week after dosing ^[2]. That's the actual data point people are referencing, however loosely, when they talk about CJC-1295's long action. Worth saying plainly: this is a research peptide. It is not an FDA-approved drug for any indication, and there's no FDA-reviewed prescribing information, dosing label, or safety monitoring protocol behind any version sold today ^[3].

What's the difference between CJC-1295 with DAC and without DAC?

This is the single most confused point in the whole topic, so here's the plain version. CJC-1295 with DAC is the original molecule from the 2006 study, the one with the albumin-binding tag that gives it a multi-day half-life (published estimates put it around 6.8 days in that trial) ^[2]. A single injection keeps GH and IGF-1 elevated for about a week, which is why it was originally investigated as a twice-monthly or weekly dosing candidate. CJC-1295 without DAC, usually sold and discussed as "Mod GRF 1-29," is a shorter fragment without the albumin-binding tag. Its half-life is roughly 30 minutes, sometimes cited in the range of minutes to under an hour depending on the source, because without DAC it clears the way native GHRH does, just a bit slower due to the amino acid substitutions ^{[1] [1]}. That difference changes the whole practical logic of use. DAC creates a standing, somewhat flattened elevation in GH over days. No-DAC creates a sharp, short pulse that's meant to be timed around a natural GH pulse, typically before bed or before training, and is why it's almost always dosed multiple times a week versus DAC's twice-weekly or weekly pattern in forum protocols (again, forum protocols, not clinical dosing). | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |

Why is CJC-1295 paired with ipamorelin?

The pairing rationale is mechanistic, not a proven clinical outcome. CJC-1295 is a GHRH analogue, it pushes on one arm of GH release. Ipamorelin is a ghrelin receptor agonist (a GH secretagogue in the same family as GHRP-6 and GHRP-2, but more selective), which pushes on a separate arm. Because the two peptides act through different receptors, the theoretical case is that combining them produces a bigger, more synchronized GH pulse than either alone, since GHRH increases GH synthesis and release while ghrelin-receptor agonists amplify the pulse and blunt somatostatin's braking effect on the pituitary ^[4]. That two-receptor logic is well established in endocrinology generally. What's not established is that this specific combination, at whatever doses people are actually injecting outside a lab, produces a meaningfully better outcome (more lean mass, better sleep, whatever the goal) than CJC-1295 alone, or than approved GH therapies. No large randomized trial has tested the CJC-1295 plus ipamorelin combination in the population using it today. The support is pharmacological logic plus small mechanism studies on the individual components, not a head-to-head outcomes trial. If you want the honest read on whether the combo is worth the extra cost and injection, is cjc-1295 worth it and cjc-1295 pros and cons both address that directly.

Is CJC-1295 legal and is it FDA-approved?

No version of CJC-1295 is FDA-approved for human use. It has no FDA-reviewed indication, label, or dosing guidance ^[3]. It's commonly sold labeled "for research use only, not for human consumption," which is a real regulatory category, but one meant for lab reagents, not a workaround for personal use. The FDA's compounding guidance documents have specifically flagged CJC-1295 among peptides that raise safety concerns when compounded for patient use, including questions about the quality of the bulk substance and lack of adequate safety data ^[5]. Separately, growth hormone secretagogues and related peptides have drawn attention under anti-doping rules; the World Anti-Doping Agency lists GH-releasing peptides and GHRH analogues as prohibited substances for competing athletes ^[6]. If you're a tested athlete, this matters regardless of anything else in this article. Bottom line on legality: buying and possessing research chemicals isn't the same as it being legal for a clinician to prescribe or compound them for you as a treatment, and the regulatory posture toward CJC-1295 specifically has gotten more restrictive, not less, in recent years.

What does CJC-1295 actually do in the body, according to studies?

The core human data point is a 2006 study in healthy adults published in the Journal of Clinical Endocrinology & Metabolism, testing single and multiple doses of CJC-1295 (with DAC). It found a dose-dependent increase in GH and IGF-1, with the higher dose tested producing sustained IGF-1 elevations described by the authors as maintained "for 9 to 11 days" after a single injection at the highest dose level studied, and repeated dosing over multiple weeks sustaining elevated IGF-1 throughout the dosing period ^[2]. That's a real, peer-reviewed finding. It is also, as far as the publicly available literature shows, close to the extent of controlled human data on this specific molecule. There isn't a body of large-scale randomized trials on body composition, strength, sleep quality, or long-term safety outcomes with CJC-1295 the way there is for, say, approved recombinant human growth hormone in specific deficiency conditions. Most of what circulates as "results" (fat loss, better sleep, thicker skin, faster injury recovery) comes from user reports, not measured trial endpoints. That's not automatically wrong, but it's a different category of evidence than what the study above generated, and it's worth being clear-eyed about which is which when you're reading claims. The cjc-1295 before and after and cjc-1295 results timeline pages walk through what a realistic timeline of self-reported change looks like, separate from the clinical data.

How is CJC-1295 typically dosed (and why do sources disagree)?

Sources disagree because there's no FDA-approved label to point to, so every dosing figure you see is either extrapolated from the 2006 trial, borrowed from compounding pharmacy protocols under physician supervision, or copied from forum posts with no verification behind them. In the actual clinical trial, doses studied included single injections up to 60 micrograms per kilogram of body weight and repeated-dose regimens at lower per-kilogram amounts given every 3 or 6 days over multiple weeks ^[2]. Translating a per-kilogram research dose into a flat "2 mg twice weekly" type instruction, which is what you'll see all over retail sites and forums, isn't something the study itself did or supports directly. Because no-DAC CJC-1295 clears in about 30 minutes, forum protocols for it tend toward small, frequent doses (commonly discussed in the 100 to 300 microgram range per injection, several times a week), timed around sleep or training. Because DAC CJC-1295 stays active for days, protocols for it tend toward less frequent, often larger single doses. None of these specific numbers come from a regulatory body; they're consensus estimates from compounding pharmacies and long-running user reports, not verified clinical dosing. If a source gives you a single confident number with no range and no caveat about where it came from, that's a signal to be skeptical, not reassured.

What are the side effects and risks of CJC-1295?

The 2006 human trial reported the treatment as generally well tolerated at the doses tested, with injection site reactions (redness, itching) as a commonly noted effect, and no serious adverse events attributed to the drug in that study population ^[2]. That's a small, short trial in healthy volunteers, not a long-term safety dataset. Beyond that trial, the side effect profile people report (through forums, and through general knowledge of what GH elevation does) includes water retention, joint discomfort, flushing or tingling right after injection, increased hunger, and in the case of no-DAC dosing, a short-lived drop in blood pressure or lightheadedness some users report right after injecting. GH and IGF-1 elevation, chronically, is also linked in the broader endocrine literature to worsened insulin sensitivity, which is why anyone with a personal or family history of diabetes should be cautious ^[7]. Because supply comes from unregulated "research chemical" vendors rather than pharmaceutical manufacturing, the bigger practical risk for most people isn't the molecule's known pharmacology, it's not actually knowing what's in the vial. FDA warning letters and compounding risk alerts around peptides generally flag contamination, incorrect concentration, and mislabeled product as recurring problems in this market ^[5]. Anyone considering this should read a straight-through safety and risk breakdown before touching a vial, and cjc-1295 pros and cons is built for exactly that comparison.

How long does it take to see results from CJC-1295?

Based on the pharmacokinetics from the 2006 trial, a single DAC injection raises IGF-1 within roughly 24 to 48 hours, with levels staying elevated for about a week after one dose, and staying elevated throughout a multi-week repeated-dosing schedule ^[2]. That's a hormone-level timeline, not a body-composition timeline. Subjective or physical changes people report (sleep quality, recovery, skin, slow body composition shifts) take much longer to show up if they show up at all, and there's no controlled trial measuring those endpoints on this molecule specifically to give you a reliable week-by-week expectation. Anything you read stating a specific week-by-week timeline for muscle gain or fat loss on CJC-1295 is extrapolation from user reports, not measured data. For a grounded, source-separated look at what a realistic timeline actually looks like, cjc-1295 results timeline lays out what's hormone-level (backed by the trial) versus what's anecdotal.

Does CJC-1295 actually work, and what's the success rate?

"Success rate" isn't a number that exists for CJC-1295 in any measurable, published sense, because there's no large trial measuring a defined outcome (like percent of users achieving a target IGF-1 increase, or percent reporting satisfaction) that would let you calculate one honestly. What does exist: the 2006 trial showed a GH and IGF-1 response in essentially all treated subjects at adequate doses, meaning the pharmacology reliably does what it's supposed to do, raise these hormone levels, in a controlled setting ^[2]. Whether that hormone-level response translates into whatever result an individual user is chasing (visible fat loss, strength gains, better sleep) is a separate question that the trial wasn't designed to answer and that no comparable trial has answered since. Anyone quoting you a specific "success rate" percentage for CJC-1295 is not quoting a real study; treat that number as marketing. For a full breakdown of what "working" would even mean here and how to think about it honestly, see cjc-1295 success rate.

Is CJC-1295 worth it compared to other options?

That depends entirely on what you're comparing it to and what you're optimizing for, which is a longer conversation than a FAQ answer can responsibly settle. Against FDA-approved recombinant human growth hormone for a diagnosed deficiency, CJC-1295 isn't a substitute; it's an unapproved peptide with a fraction of the safety monitoring and none of the regulatory oversight. Against doing nothing and just optimizing sleep, training, and diet, which reliably raise natural GH pulses at zero cost and zero legal ambiguity, CJC-1295 is an expensive and legally gray bet on a mechanism that's real but whose downstream benefit is not clinically proven for the population using it recreationally. Cost is a real factor too: research-grade CJC-1295 and ipamorelin typically run somewhere in the range of $60 to $150+ per vial depending on dose and supplier, and most protocols need multiple vials a month, which adds up fast for something with no guaranteed outcome. The most complete side-by-side on this exact question lives at is cjc-1295 worth it, which walks through the cost, the evidence gaps, and the alternatives in one place.

How should I evaluate a source or supplier for CJC-1295?

Given everything above, sourcing quality is arguably the biggest practical risk factor, bigger than the molecule's known pharmacology. A provider-reviewed route means a pharmacy or clinical partner has actually reviewed the product and sourcing rather than a random storefront drop-shipping vials labeled "research use only." CJC-1295 Co reviews providers along these lines and names the fulfilling pharmacy partner rather than compounding or manufacturing anything itself; that distinction, someone reviewing and connecting you to a pharmacy versus an anonymous chemical vendor, is the single highest-leverage decision most people make in this whole space, more consequential than which specific dose or protocol they pick. Whatever route you take, basic diligence applies: ask for a current certificate of analysis from a third-party lab, avoid any seller who won't disclose sourcing, and treat aggressive dosing claims or promised outcomes as a red flag rather than a selling point.

Frequently asked questions

What is the difference between CJC-1295 and Ipamorelin?

CJC-1295 is a GHRH analogue that boosts GH production and release through the GHRH receptor. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue) that boosts GH release through a different receptor and is more selective than older secretagogues like GHRP-6. They're often paired because they act on separate receptors, not because one replaces the other.

What is the difference between CJC-1295 with DAC and without DAC?

DAC (Drug Affinity Complex) is a chemical tag that lets CJC-1295 bind albumin in blood, stretching its half-life to roughly 6.8 days per the 2006 human trial. Without DAC, the peptide (often called Mod GRF 1-29) clears in about 30 minutes, producing a short, sharp GH pulse instead of a sustained elevation.

Is CJC-1295 FDA-approved or legal to buy?

No. CJC-1295 has no FDA approval for any human use and no FDA-reviewed label or dosing guidance. It's typically sold as a research chemical, a category meant for lab use, not personal injection. FDA compounding guidance has flagged it among peptides with unresolved safety concerns.

How long does CJC-1295 stay in your system?

CJC-1295 without DAC has a half-life around 30 minutes. CJC-1295 with DAC has a half-life around 6.8 days based on the 2006 clinical trial, with IGF-1 levels staying elevated for roughly 6 to 11 days after a single higher-dose injection.

What are the main side effects of CJC-1295?

The 2006 trial reported mostly injection site reactions like redness and itching, with the treatment described as generally well tolerated at studied doses. Users commonly report water retention, joint discomfort, flushing, and increased hunger, though long-term safety data doesn't exist for this peptide.

Do CJC-1295 and Ipamorelin work better together than alone?

Mechanistically it makes sense: they act on different receptors (GHRH receptor vs ghrelin receptor), and combining GHRH analogues with ghrelin-receptor agonists is known to amplify GH pulses in endocrine research. No large trial has tested this specific combination's real-world outcomes in the population currently using it, so the combined benefit claim is plausible but unproven.

How much does CJC-1295 typically cost?

Research-grade CJC-1295 (with or without DAC) and ipamorelin typically cost somewhere in the $60 to $150+ per vial range depending on dose and supplier, with most protocols requiring multiple vials monthly. Price alone doesn't indicate quality; sourcing verification matters more than cost comparison.

Is there real clinical evidence behind CJC-1295, or is it all forum talk?

There is one key human study: a 2006 trial published in the Journal of Clinical Endocrinology & Metabolism testing CJC-1295 with DAC in healthy adults, showing dose-dependent GH and IGF-1 increases. Beyond that, most claims about body composition, sleep, or recovery come from user reports, not controlled trials.

Can CJC-1295 show up on a drug test for athletes?

Growth hormone releasing peptides and GHRH analogues, which includes CJC-1295, are on the World Anti-Doping Agency's prohibited list for competing athletes. Testing methods for GH-axis manipulation exist and are used in anti-doping programs, so tested athletes should treat this as a real risk, not a theoretical one.

How is CJC-1295 usually injected?

It's typically given as a subcutaneous injection, most often in the abdomen, similar to how insulin or other small-volume peptides are self-administered. No-DAC versions are usually dosed more frequently due to their short half-life; DAC versions less often due to their multi-day half-life. None of these schedules come from an FDA label.

Does CJC-1295 cause weight loss or fat loss?

There's no controlled trial measuring fat loss as an endpoint for CJC-1295 specifically. The rationale rests on GH and IGF-1's known roles in metabolism generally, but the leap from "raises GH" to "causes fat loss in this specific peptide's users" hasn't been tested directly in published research.

What's the difference between CJC-1295 and prescription HGH?

Prescription recombinant human growth hormone is FDA-approved for specific diagnosed conditions, manufactured under strict quality standards, and dosed under monitored care. CJC-1295 is an unapproved peptide that stimulates your own pituitary to release more GH; it isn't GH itself and carries none of the same regulatory oversight or approved-use data.

Sources

1. National Center for Biotechnology Information, PubChem: CJC-1295 (no-DAC / Mod GRF 1-29 characterization): CJC-1295 is built from a modified 29-amino-acid GHRH fragment; without DAC it has a short half-life
2. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2006: Single and repeated dosing of CJC-1295 with DAC in healthy adults produced sustained, dose-dependent GH and IGF-1 elevations lasting about 6 to 11 days, with a half-life around 6.8 days
3. U.S. Food and Drug Administration, Bulk Drug Substances list for compounding: CJC-1295 has no FDA approval and is not on the list of bulk substances cleared for compounding use
4. Endocrine Society, Clinical review on growth hormone secretagogues: GHRH analogues and ghrelin-receptor agonists act through separate receptors and can produce synergistic GH release
5. U.S. Food and Drug Administration, Insanitary Conditions and compounding risk alerts / peptide compounding concerns: FDA has flagged compounded peptides including growth-hormone-releasing peptides for unresolved safety and quality concerns
6. World Anti-Doping Agency, Prohibited List: Growth hormone releasing peptides and GHRH analogues are prohibited substances under WADA rules
7. National Institute of Diabetes and Digestive and Kidney Diseases, Growth Hormone and metabolic effects: Chronic elevation of GH and IGF-1 is associated with worsened insulin sensitivity and metabolic effects